Health · Cambridge, Massachusetts, US · United States of America · October 23, 2026

Personalized mRNA vaccine cuts melanoma recurrence risk in trial

Reported by 2 outlets · first reported Oct 23, 12:27 AM ET

Trial results show intismeran, a personalized mRNA vaccine from Moderna and Merck custom-made for each patient's tumor, significantly reduced the risk of melanoma recurrence or death within two years after surgery. Six melanoma specialists told CNBC the results are clinically meaningful, despite a negative reaction from Wall Street.

Why it matters

It supports a new personalized approach to cancer treatment that uses the patient's own immune system.

Background

Melanoma is the most dangerous form of skin cancer. mRNA technology was widely used in COVID-19 vaccines and is being adapted for cancer.

The story so far

1. Oct 23Personalized mRNA vaccine cuts melanoma recurrence risk in trial
2. Oct 24Doctors back Moderna-Merck melanoma vaccine results

Follow the whole story →

Sources

• Guardian Science ↗Oct 23, 12:27 AM ET
• CNBC ↗Oct 23, 1:15 PM ET

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Oct 23's stories